about
Primary HIV-1 infection: a review of clinical manifestations, immunologic and virologic changes.Barriers to HIV testing and characteristics associated with never testing among gay and bisexual men attending sexual health clinics in Sydney.Multi-centre field evaluation of the performance of the Trinity Biotech Uni-Gold HIV 1/2 rapid test as a first-line screening assay for gay and bisexual men compared with 4th generation laboratory immunoassays.Performance evaluation of a new fourth-generation HIV combination antigen-antibody assayMulti-centre evaluation of the Determine HIV Combo assay when used for point of care testing in a high risk clinic-based population.Prevalence, incidence and risk factors for pharyngeal chlamydia in the community based Health in Men (HIM) cohort of homosexual men in Sydney, Australia.Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia.Quality assuring HIV point of care testing using whole blood samples.Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study.Development of a clinical algorithm to prioritise HIV testing of hospitalised paediatric patients in a low resource moderate prevalence setting.Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection.Effect of testing experience and profession on provider acceptability of rapid HIV testing after implementation in public sexual health clinics in Sydney.Development of a cost-effective assay for genotyping of HIV-1 non-B subtype for drug resistance.Kaposi's sarcoma-associated herpesvirus: a sexually transmissible infection?Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification.Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection.Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion.Positive Epstein-Barr virus and cytomegalovirus IgM assays in primary HIV infection.Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group.Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis.Evaluation of the Xpert® HCV Viral Load Fingerstick point-of-care assay.Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid.False negative HIV-1 proviral DNA polymerase chain reaction in a patient with primary infection acquired in Thailand.Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot SamplesAssociation between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in AustraliaIdentification of HIV-1 in semen following primary HIV-1 infectionPredictors of progression in long-term nonprogressors. Australian Long-Term Nonprogressor Study GroupTreatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individualsPhenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1-infected patients treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNAIncidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populationsLessons learnt from the first Australian 'pop-up' HIV testing siteEvaluation of an interferon-gamma release assay in children with suspected tuberculosis in Papua New GuineaResponse to the modeling analysis by Katz et al. on the impact of replacing clinic-based HIV tests with home testing among men who have sex with men in Seattle
P50
Q34256775-1D53F894-390D-4531-8019-5BD7D00083DBQ36005134-358242E5-980F-4D49-961D-DD7FE8029B06Q36212595-EA61D4A9-6980-4C17-A2B4-A7B573AB9B12Q36582087-A865F2BF-57F8-4DE2-B30B-677E60527B8CQ37692346-833A3DE3-777A-42A3-8632-A444680A130DQ37857119-774885B9-9A6A-4655-82C3-2770B08E9BABQ38746110-AA1CC557-3182-4D30-97E5-2986F564933FQ39680788-ADF229EF-58AE-447E-BD76-C9C234D58AC1Q40228317-5C21E2DF-04E8-4B9E-AD71-668662C68B7CQ40344504-6EEED118-43E4-443B-8D4D-89AD88F8CCF9Q41300550-B6653A65-5798-4DD9-9BDA-C36BB1C0EFEFQ41554728-E5FFE208-E18C-4404-8A63-27F93A1C8845Q42241195-D2A50F43-2B70-46AB-97FF-4213ED4E977DQ42595856-D1690866-4FBD-4BB1-80CB-0C73D0838515Q43606007-FB645FD7-AE33-42B2-95DC-D06083D2030AQ43752202-EFCF4294-55AF-4F49-8E06-2DCE528D568BQ43869599-C6E1D72C-9F35-4B4D-842A-694894621CA6Q44399529-B586F650-1F0D-4B30-BC39-80F3624BFF44Q45365676-A01EE170-53BD-4740-B05C-0788E1EB0325Q45752836-D78A4E75-AC38-4D28-A33F-6A7E23E4B20EQ47594606-45705FB4-4453-42D8-81BC-BD60E6B5B985Q52657938-4DD19C09-9DCE-48E6-873C-BD052BE7A067Q54036208-4E643FC9-C697-4E85-B8F0-3294BB1FF2E1Q54788124-E46F0C53-415C-49F5-B9E6-B78941AEC78FQ58033017-47E7A422-2924-4875-BC3B-8CBFA9CAF84EQ58118714-E6B08FAA-5493-4A83-BED7-10782B78FE30Q67548430-E986F457-B000-4ACA-A3EA-D6BC4B6C0BE7Q74173198-761F4A74-CDD1-4C2A-B10F-3E8201CB85C6Q77386263-DF7D36A0-10FD-4925-BE49-13AE9B5BB02BQ78121230-3EFAE21B-9E5E-4BD0-8E08-6F00614ACAF1Q81091989-796165DD-DB96-45DC-AEBB-592A052EF0B3Q86039149-42D18ABC-0D85-40FD-9AEC-0235C4C2EE52Q87376776-1BBB8504-985E-4D0D-8CC2-76146D8951D8Q87658281-E4213C41-6D49-4A45-99F5-6378576F0F46
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
研究者
@zh
name
P Cunningham
@ast
P Cunningham
@en
P Cunningham
@es
P Cunningham
@nl
type
label
P Cunningham
@ast
P Cunningham
@en
P Cunningham
@es
P Cunningham
@nl
prefLabel
P Cunningham
@ast
P Cunningham
@en
P Cunningham
@es
P Cunningham
@nl
P31
P496
0000-0003-2613-6910